Navigation Links
Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line

BEIJING, July 13 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced today that it has acquired an emergency ventilator product line (QS-100A series) from Beijing Qiumanshi Technology Co., Ltd. The acquisition includes the production technology and complete proprietary intellectual property.

(Logo: )

(Logo: )

The QS-100A series is a multi-functional emergency, portable synchronized ventilator. It is pneumatic-driven and gas-controlled, requiring no other power supply. Because of its compact size and low weight, it can be effectively used on the scene in accident cases and during patient transportation.

Dehaier CEO Ping Chen said, "This acquisition complements our ventilator product line. Dehaier already has well-established ventilator products for home use and hospital use. Our latest product now allows us to provide portable ventilator products for use at a medical emergency site as well as during ambulance transport to the hospital."

Dehaier estimates the annual demand for emergency ventilators in China is approximately RMB150 million (US$22 million). The company expects production capacity to reach 2,000 units per year, suggesting an annual product revenue of RMB 20 million (US$2.9 million).

Chen added, "This acquisition qualifies Dehaier to participate in the 11th five-year rural cooperative medical service development project for emergency medical products, and expands our company's respiratory care product range. We are really pleased to add a portable ventilator that can be carried by rescue units for emergency use. We intend to continue to broaden our product lines to better serve our growing customer base."

About Beijing Qiumanshi Technology Co., Ltd.

Beijing Qiumanshi Technology Co., Ltd. is an operating entity that combines designing, developing, manufacturing, distributing and service providing. Its products have been widely used in China and exported to Brunei and Africa. Company website: .

About Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier's technology is based on two patents, five pending patents and proprietary technology. More information may be found at .

Information for investors, including an investment profile about Dehaier is available at . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at .

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Investor contact:
     Hawk Associates
     Julie Marshall or Frank Hawkins
     Tel:   +1-305-451-1888

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Systems Announces Closing of Initial Public Offering on NASDAQ
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. Dehaier Medical Systems Announces New Exclusive China Distribution Agreement with Welch Allyn, Further Broadening Companys Product Lines
4. Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell
5. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Globus Medical Raises $110 Million in Series E Financing Round
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Boston University Biomedical Engineers Find Chink in Bacterias Armor
Post Your Comments:
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):